the aid library

LIST OPTIONS

Filter

726

Australian guidelines for the clinical care of people with MPX

Australian National Clinical Evidence Taskforce (2022) C1

Nov 11, 2022

External Link

Molecular and Clinical Aspects of Chronic Manifestations in Chagas Disease: A State-of-the-Art Review

Medina-Rincón, G.; Gallo-Bernal, S.; Jiménez, P.; et al. (2021) CC

Pathogens . 2021 Nov 16;10(11):1493.doi: 10.3390/pathogens10111493 .Chronic manifestations of Chagas disease present as disabling and life-threatening condi-tions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mech... more

External Link

Breaking the silence an Opportunity for Patients with Chagas Disease

Moriana, S.; Oritz, G.; Fanjul, G. Chagas Coalition (2016) CC

Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is an appropriate time to celebrate what has been ach... more

External Link

The global burden of chromoblastomycosis

Santos, D.; Pedrozo e Silva de Azevedo, C.; Aparecida Vincent, V. et al. (2021) CC

Chromoblastomycosis (CBM), represents one of the primary implantation mycoses caused by melanized fungi widely found in nature. It is characterized as a Neglected Tropical Disease (NTD) and mainly affects populations living in poverty with significant morbidity, including stigma and discrimination.

External Link

Vector-borne diseases: a handbook for pharmacists - Disease prevention, control, management and treatment

Gromek K., Hung M., Montero N. et al International Pharmaceutical Federation FIP (2020) C2

The Pharmaceutical Forum of the Americas (PFA) has previously published guidelines and organised campaigns for community pharmacists on the prevention, detection and control of arbovirus infections in 2018 with a grant from the FIP Foundation for Pharmacy Education and Research. Building on that exp... more

Download (289)

View PDF (385)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Kenya National Guidelines for Cardiovascular Diseases Management

Ministry of Health Kenya Republic of Kenya (2018) CC

The Kenya Health Policy 2014-2030 aims at attaining the highest possible standard of health in a manner responsive to the health needs of our population. One of the major policy directions towards realizing the intentions of this policy is to halt and reverse the rising burden of non-communicable d... more

External Link

Sources And Prices Of Selected Medicines for Children
recommended

Unicef, WHO (2010) C_WHO

Including Therapeutic Food, Dietary Vitamin and Mineral Supplementation - 2nd edition

Rabies Vaccines WHO position paper

WHO (2007)

Download (837)

View PDF (1622)

Introduction to the Core Curriculum on Tuberculosis: What the Clinician Should Know

Center for Disease Control and Prevention (2013)

Sixth Edition

Download (1702)

View PDF (1846)

National Guidelines for the Management of Tuberculosis in Children

National Tuberculosis Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Bangladesh (2016) C1

2nd edition

Download (838)

View PDF (1556)

PRINCIPLES AND PRACTICE OF BIOETHICS : CASE - STUDIES IN WOMEN’S HEALTH

By the Committee on Ethical Aspects of Human Reproduction and Women's Health, International Federation of Gynaecologists and Obstetricians (FIGO) (2012)

This curriculum can be used freely in order to stimulate means of ethical analysis, reflection and decision-making.

Download (636)

View PDF (853)

National HIV and AIDS , STI Policy

Ghana AIDS Commission (2013) C1

Download (810)

View PDF (1694)

Questions and Answers About Tuberculosis
recommended

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Centers for Disease Control and Prevention (2014) C_CDC

External Link

simple definitions for keywords about blood-borne viruses and sexual health

Multicultural Health & Support Service (2015) C2

The BBV/STI Glossary is a resource for interpreters, translators and others who work in a health setting. It offers an extensive list of English terms related to sexual health and blood-borne viruses (such as hepatitis), with easy to understand definitions. Accessed 13th of November 2015.